title: Antagonist effect of pseudohypericin at CRF1 receptors.
abstract: St. John's wort (Hypericum perforatum L.) is widely used for the treatment of mild to moderately severe depression. However, the nature of its active principles and the exact mode of antidepressant action are still unknown. It has been suggested repeatedly in preclinical and clinical studies that the content of the acylphloroglucinol hyperforin decisively contributes to the antidepressant efficacy of St. John's wort extracts. Experimental studies in vivo also indicate that the naphthodianthrone hypericin may reduce the activity of the hypothalamic-pituitary-adrenal axis. Exacerbated hypothalamic-pituitary-adrenal activity has often been associated with depressive states in patients. Corticotropin-releasing factor (CRF) seems to be a major determinant in the regulation of the hypothalamic-pituitary-adrenal activity via activation of CRF(1) receptors. In the present study, we investigated the CRF(1) receptor antagonist activity of three main constituents of St. John's wort (hypericin, pseudohypericin and hyperforin) by measuring their effect on CRF-stimulated cAMP formation in recombinant Chinese hamster ovary (CHO) cells. As a selectivity test, the compounds were also tested against calcitonin in the same cells. Of the three compounds tested, only pseudohypericin selectively antagonised CRF (K(B) 0.76 microM). Hypericin and hyperforin affected both CRF and calcitonin with similar potencies and the same type of behaviour (competitive antagonism for hypericin, noncompetitive for hyperforin). It is concluded that pseudohypericin is the only real CRF(1) receptor antagonist of the three constituents tested. In addition, evidence is provided that beside hyperforin, both pseudohypericin and hypericin are implicated in the antidepressant efficacy of St. John's wort.
authors.affiliation: Institute of Pharmaceutical Biology, University of Basel, Witterswil, Switzerland. usimmen@datacomm.ch
authors.forename: Urs
authors.initials: U
authors.lastname: Simmen
authors.forename: Ionel
authors.initials: I
authors.lastname: Bobirnac
authors.forename: Christoph
authors.initials: C
authors.lastname: Ullmer
authors.forename: Hermann
authors.initials: H
authors.lastname: Lübbert
authors.forename: Karin
authors.initials: K
authors.lastname: Berger Büter
authors.forename: Willi
authors.initials: W
authors.lastname: Schaffner
authors.forename: Philippe
authors.initials: P
authors.lastname: Schoeffter
mesh_terms: D000818:Animals; D000873:Anthracenes; D001643:Bridged Bicyclo Compounds; D016466:CHO Cells; D002116:Calcitonin / Q000494:pharmacology; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010569:Perylene / Q000031:analogs & derivatives* / Q000494:pharmacology*; D010696:Phloroglucinol / Q000031:analogs & derivatives; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D013729:Terpenes / Q000494:pharmacology; D014162:Transfection; D000099052:CRF Receptor, Type 1
chemical_list: D000873:Anthracenes; D001643:Bridged Bicyclo Compounds; D018019:Receptors, Corticotropin-Releasing Hormone; D013729:Terpenes; D000099052:CRF Receptor, Type 1; D010569:Perylene; C004965:hypericin; D002116:Calcitonin; D003346:Corticotropin-Releasing Hormone; D010696:Phloroglucinol; D000242:Cyclic AMP; C056602:pseudohypericin; C001654:hyperforin